(FOA)-Conduct Studies to Establish More Targeted Durations of Use for Certain Approved Antimicrobial New Animal Drugs in Food Animals (U01) Clinical Trials Optional; May 1, 2020

 

Agency

U.S. Food and Drug Administration

 

Description

The purpose of this Funding Opportunity is to solicit applications to generate evidence that could support the approval of label changes to establish more targeted durations of use for certain approved medically important antimicrobial new animal drugs in food animals. These cooperative agreements are intended to provide publicly available evidence to be used by sponsor(s) of affected approved new animal drugs to fulfill a portion of or all of the requirements for the effectiveness technical section for the approval of future supplemental new animal drug applications. Such supplemental new animal drug applications are intended to:

1) Revise approved dosage regimens to provide for use durations that are more targeted (i.e., are more specifically defined) and,

2) That the revised dosage regimens continue to provide effectiveness that is comparable to the currently approved regimen while reducing the risk of antimicrobial resistance

development.  

 

See list of affected new animal drug applications at [List of Approved Medically Important Antimicrobial Drugs Administered in the Feed of Food-Producing Animals that Lack a Defined Duration of Use.].

 

Announcement Number:

RFA-FD-20-025

 

Closing Date:

May 1, 2020

 

Link to Full Announcement

https://grants.nih.gov/grants/guide/rfa-files/RFA-FD-20-025.html

 

Contact Information

Rita Viskup

240-402-1568

Rita.Viskup@fda.hhs.gov